EAA / BCAA
Also sold as: Essential amino acids · Branched-chain amino acids · Leucine isoleucine valine
EAA mixtures supply all nine essential amino acids; BCAA supply only leucine, isoleucine and valine. BCAA are marketed for workout recovery but cannot provide all substrates needed to build muscle protein.
Energy
Community
Not enough ratings yet: 0 of 10
Scores appear after 10 ratings, so that one or two reports can't dominate. Tried it? Your rating counts.
Research
- Energy: Some short exercise trials report less fatigue or better performance, especially in untrained men; results are inconsistent and soreness reduction does not establish improved muscular function.
REALITY CHECK // Less soreness is not the same as restored strength: the meta-analysis found damage-marker and soreness changes without a significant muscular-performance benefit. BCAA are incomplete building material, while EAA and complete protein supply the missing amino acids. Cirrhosis evidence cannot be used as proof of longer life in healthy athletes.
Levels: how we grade evidence. Grey = evidence of no benefit; amber = evidence it makes this goal worse.
Ratings are self-reported by a self-selected group of users: how it felt, not proof that it works.
Check your bottle
Compare what your label says with what was used in trials. This is a trial range, not a personal prescription.
Enter the amount from your label to see the result.
How it was studied
UPPER LIMIT // No formal EFSA or NIH upper intake level is supplied for BCAA/EAA. Long-term safety above 20 g/day in healthy people is insufficiently established; higher clinical exposures are not a general safety ceiling.
Summary
A small acute BCAA trial increased muscle protein synthesis, but BCAA lack the other essential substrates supplied by EAA or complete protein. Soreness and biochemical damage markers may improve without faster strength recovery. Clinical hepatic-encephalopathy use is distinct from sports supplementation and has little or no established mortality benefit.
Mechanism
Leucine activates mTORC1 signaling; sustained new protein synthesis needs all EAA. BCAA compete with other large neutral amino acids for transport, which underlies levodopa interaction concerns and the unconfirmed central-fatigue hypothesis.
Typical studied dose
BCAA studies used about 5-20 g/day; one acute resistance-exercise trial used 5.6 g. Clinical studies sometimes describe about 30 g/day under supervision. The supplied dossier gives no general numerical EAA trial range and no optimal amino-acid ratio.
Upper limit
No formal EFSA or NIH upper intake level is supplied for BCAA/EAA. Long-term safety above 20 g/day in healthy people is insufficiently established; higher clinical exposures are not a general safety ceiling.
Popular stacks with EAA / BCAA
Not enough stack data yet. A combination with EAA / BCAA appears here once 5 people rate the same set.
Forms and label traps
| Form on label | Active content | Studied range / day | Absorption & GI tolerance | Verdict |
|---|---|---|---|---|
| Free-form BCAA 2:1:1 Best for: Matching actual BCAA trials. |
Extract weight · ~100% marker | 5000–20000 mg | Rapidly absorbed free amino acids; ratio superiority is unproven. Usually tolerated at 5-10 g, but high boluses can cause GI effects. |
Studied standard REFERENCE 100% means amino-acid ingredient mass, not elemental-mineral conversion; all mixture components must be disclosed. |
| Complete nine-EAA mixture Best for: Supplemental amino acids when adequate complete protein is impractical. |
Unstandardized: active content unknown | no comparable trial range | Supplies all essential substrates rather than only three branched-chain amino acids. Usually tolerated, composition-dependent. |
Good option GOOD No universal EAA dose or leucine fraction is supplied. Do not compare an unspecified nine-amino-acid mixture with the BCAA trial interval. |
| Hydrolyzed peptide products Best for: Label-specific assessment only. |
Unstandardized: active content unknown | no comparable trial range | No established clinical superiority to free amino acids in this dossier. Product-dependent; comparative evidence is lacking. |
Caution CAUTION Peptide and amino-acid proportions vary; no verified conversion or universal trial range. |
| BCAA capsules versus powder Best for: Price and convenience after checking net amino-acid mass. |
Extract weight · ~100% marker | 5000–20000 mg | Delivery format alone does not establish a clinical absorption advantage. Individual tolerance and excipients matter. |
Good option GOOD Compare the BCAA ingredient amount, excluding flavoring/fillers. This is a dosage format, not a new active substance. |
Common label traps
- TRAP_01 // BCAA build more muscle than protein
The acute signal is not long-term hypertrophy evidence; complete protein already provides BCAA plus the other needed amino acids. - TRAP_02 // Less soreness means faster strength recovery
The meta-analysis found no significant muscular-performance difference despite soreness and damage-marker improvements. - TRAP_03 // 2:1:1 or 8:1:1 is scientifically optimal
The dossier contains no human head-to-head evidence establishing the best ratio. - TRAP_04 // BCAA preserve muscle during weight loss
The overweight/obesity weight-loss RCT did not preserve lean mass or improve metabolic profile.
Other outcomes studied
Outside the five leaderboard goals. Same evidence levels as above.
- ACUTE_MUSCLE_PROTEIN_SYNTHESIS Limited · benefit
In 10 young trained men, 5.6 g BCAA after resistance exercise increased myofibrillar protein synthesis 22% versus placebo (P=0.012). This acute study is not evidence of superior long-term muscle gain over complete protein.
PMID 28638350 PMID 28852372 - SORENESS_DAMAGE_MARKERS Moderate · benefit
A 25-study synthesis in 479 adults found lower damage markers at 48 h (SMD -0.41) and less soreness at 24-48 h. Functional muscular performance was not significantly different (SMD 0.08-0.21).
PMID 34612716 PMID 38625669 PMID 34669012 PMID 30938579 - HEPATIC_ENCEPHALOPATHY Moderate · benefit
Systematic reviews support improvement in hepatic encephalopathy in cirrhosis, with little or no mortality benefit. This is supervised clinical nutrition, not healthy-athlete longevity evidence.
PMID 41542879 PMID 35500317 PMID 28518283 - SARCOPENIA Limited · benefit
BCAA-rich nutrition plus resistance training may improve body composition/function in older sarcopenic patients. Leucine/MPS signals and mixed lean-mass data coexist with a review finding no significant augmentation of training by protein supplementation; supplementation alone is not a reliable substitute for training.
PMID 41202431 PMID 25234223 PMID 32483625 PMID 27670605 - EXERCISE_FATIGUE Limited · benefit
Short trials report better cycling in untrained participants and altered substrate use/less fatigue in active young men. A systematic review distinguishes biochemical signals from inconsistent clinical performance evidence.
PMID 33162329 PMID 40219047 PMID 41655197 - METABOLIC_RISK Limited · no benefit
Higher circulating BCAA predict type 2 diabetes observationally; this may mark impaired metabolism and does not prove supplements cause diabetes. The overweight/obesity supplementation RCT found no metabolic benefit.
PMID 36297095 PMID 33537760 - WEIGHT_LOSS_LEAN_MASS Limited · no benefit
The weight-loss RCT did not preserve lean mass or improve metabolic profile. Amino-acid marketing does not establish fat loss or anticatabolic protection.
PMID 33537760 PMID 40573110 - CANCER_CACHEXIA Limited · benefit
A systematic review found limited, mixed evidence for nutritional interventions including BCAA in cancer cachexia; clinical supervision is essential.
PMID 35888685 - MIGRAINE_TRIGGER Anecdotal · makes it worse
A single case report describes migraine without aura after BCAA supplementation. This is a possible adverse signal, not established causation or treatment evidence.
PMID 42316353
Reader questions
BCAA or EAA?
All nine EAA are needed to build new protein. BCAA alone provide a leucine signal plus only two other essential amino acids; complete protein or a complete EAA mixture addresses the missing substrates.
Are BCAA worth adding if I already take whey?
Whey already supplies BCAA and the other essential amino acids. Additional BCAA have no established routine additive muscle-gain benefit.
Will they reduce soreness and restore strength faster?
Soreness may fall at 24-48 hours, but pooled muscular-performance recovery was not significantly improved.
Can a teenager or someone with a metabolic disease use them?
Unsupervised high-dose use is not established in minors. MSUD is an absolute contraindication; kidney disease, urea-cycle disorders or liver disease need medical nutrition review.
Do elevated blood BCAA prove supplementation causes diabetes?
No. Observational circulating concentrations can reflect impaired metabolism. They do not demonstrate that a BCAA supplement causes diabetes or establish a metabolic benefit.
Stack interactions
- Caution Levodopa [CAUTION]
BCAA and other large neutral amino acids compete with levodopa transport. Review high-dose supplements with the treating Parkinson disease team; the cataloged molecular study is mechanistic/preclinical.
PMID 25073474 - Caution Complete protein / whey [CAUTION]
Complete protein already provides BCAA and the remaining essential amino acids. Routine duplication is not evidence of extra hypertrophy.
PMID 28852372 - Caution Diabetes medicines [CAUTION]
A chronic-hepatitis-C insulin-resistance trial reported glycemic changes, while an obesity weight-loss trial found no metabolic benefit. Do not generalize either to a reliable diabetes treatment or quantified drug interaction.
PMID 22520843 PMID 33537760 - Caution Tryptophan / 5-HTP / antidepressants [CAUTION]
Competition for large-neutral-amino-acid brain transport is a theoretical concern at high doses; a clinically established SSRI/SNRI interaction is not documented here.
Red flags: interactions and who should avoid it
Interactions
Large neutral amino acids can compete with levodopa absorption/brain transport; review dosing with the treating team. Diabetes medicines warrant monitoring, with limited disease-specific data. Tryptophan/5-HTP or antidepressant interactions are theoretical rather than established clinical events. Complete protein already contains BCAA; creatine has a separate mechanism.
Avoid or ask a doctor first if
Maple syrup urine disease is an absolute contraindication to BCAA supplementation. Liver encephalopathy, renal disease and urea-cycle disorders require medical nutrition care; BCAA can increase exercise ammonia. Avoid unsupervised high-dose use in pregnancy, breastfeeding or minors. High single doses can cause GI symptoms; a single migraine-trigger case is a weak safety signal.
Sources (PubMed, 23)
- Branched-Chain Amino Acid Ingestion Stimulates Muscle Myofibrillar Protein Synthesis following Resistance Exercise in Humans.
PMID 28638350 · 2017 · randomized controlled trialIn 10 young trained men, 5.6 g BCAA after resistance exercise increased myofibrillar protein synthesis 22% versus placebo (P=0.012). This acute study is not evidence of superior long-term muscle gain over complete protein.
- Branched-chain amino acids and muscle protein synthesis in humans: myth or reality?
PMID 28852372 · 2017 · narrative reviewIn 10 young trained men, 5.6 g BCAA after resistance exercise increased myofibrillar protein synthesis 22% versus placebo (P=0.012). This acute study is not evidence of superior long-term muscle gain over complete protein.
- The effect of branched-chain amino acid on muscle damage markers and performance following strenuous exercise: a systematic review and meta-analysis.
PMID 34612716 · 2021 · systematic review / meta-analysisA 25-study synthesis in 479 adults found lower damage markers at 48 h (SMD -0.41) and less soreness at 24-48 h. Functional muscular performance was not significantly different (SMD 0.08-0.21).
- Attenuating Muscle Damage Biomarkers and Muscle Soreness After an Exercise-Induced Muscle Damage with Branched-Chain Amino Acid (BCAA) Supplementation: A Systematic Review and Meta-analysis with Meta-regression.
PMID 38625669 · 2024 · systematic review / meta-analysisA 25-study synthesis in 479 adults found lower damage markers at 48 h (SMD -0.41) and less soreness at 24-48 h. Functional muscular performance was not significantly different (SMD 0.08-0.21).
- The use of BCAA to decrease delayed-onset muscle soreness after a single bout of exercise: a systematic review and meta-analysis.
PMID 34669012 · 2021 · systematic review / meta-analysisA 25-study synthesis in 479 adults found lower damage markers at 48 h (SMD -0.41) and less soreness at 24-48 h. Functional muscular performance was not significantly different (SMD 0.08-0.21).
- Effect of branched-Chain Amino Acid Supplementation on Muscle Soreness following Exercise: A Meta-Analysis.
PMID 30938579 · 2019 · systematic review / meta-analysisA 25-study synthesis in 479 adults found lower damage markers at 48 h (SMD -0.41) and less soreness at 24-48 h. Functional muscular performance was not significantly different (SMD 0.08-0.21).
- Branched-chain amino acids for people with cirrhosis and hepatic encephalopathy.
PMID 41542879 · 2026 · systematic review / meta-analysisSystematic reviews support improvement in hepatic encephalopathy in cirrhosis, with little or no mortality benefit. This is supervised clinical nutrition, not healthy-athlete longevity evidence.
- Efficacy of branched chain amino acids supplementation in liver cirrhosis: A systematic review and meta-analysis.
PMID 35500317 · 2022 · systematic review / meta-analysisSystematic reviews support improvement in hepatic encephalopathy in cirrhosis, with little or no mortality benefit. This is supervised clinical nutrition, not healthy-athlete longevity evidence.
- Branched-chain amino acids for people with hepatic encephalopathy.
PMID 28518283 · 2017 · systematic review / meta-analysisSystematic reviews support improvement in hepatic encephalopathy in cirrhosis, with little or no mortality benefit. This is supervised clinical nutrition, not healthy-athlete longevity evidence.
- Effects of branched-chain amino acid-rich nutritional supplements combined with resistance training on body composition and body function in older patients with sarcopenia.
PMID 41202431 · 2026 · systematic review / meta-analysisBCAA-rich nutrition plus resistance training may improve body composition/function in older sarcopenic patients. Leucine/MPS signals and mixed lean-mass data coexist with a review finding no significant augmentation of training by protein supplementation; supplementation alone is not a reliable substitute for training.
- The effectiveness of leucine on muscle protein synthesis, lean body mass and leg lean mass accretion in older people: a systematic review and meta-analysis.
PMID 25234223 · 2015 · systematic review / meta-analysisBCAA-rich nutrition plus resistance training may improve body composition/function in older sarcopenic patients. Leucine/MPS signals and mixed lean-mass data coexist with a review finding no significant augmentation of training by protein supplementation; supplementation alone is not a reliable substitute for training.
- Nutritional interventions to improve muscle mass, muscle strength, and physical performance in older people: an umbrella review of systematic reviews and meta-analyses.
PMID 32483625 · 2021 · systematic review / meta-analysisBCAA-rich nutrition plus resistance training may improve body composition/function in older sarcopenic patients. Leucine/MPS signals and mixed lean-mass data coexist with a review finding no significant augmentation of training by protein supplementation; supplementation alone is not a reliable substitute for training.
- Protein Supplementation Does Not Significantly Augment the Effects of Resistance Exercise Training in Older Adults: A Systematic Review.
PMID 27670605 · 2016 · systematic review / meta-analysisBCAA-rich nutrition plus resistance training may improve body composition/function in older sarcopenic patients. Leucine/MPS signals and mixed lean-mass data coexist with a review finding no significant augmentation of training by protein supplementation; supplementation alone is not a reliable substitute for training.
- Branched-chain amino acid supplementation improves cycling performance in untrained cyclists.
PMID 33162329 · 2021 · randomized controlled trialShort trials report better cycling in untrained participants and altered substrate use/less fatigue in active young men. A systematic review distinguishes biochemical signals from inconsistent clinical performance evidence.
- Branched-Chain Amino Acid Supplementation Enhances Substrate Metabolism, Exercise Efficiency and Reduces Post-Exercise Fatigue in Active Young Males.
PMID 40219047 · 2025 · randomized controlled trialShort trials report better cycling in untrained participants and altered substrate use/less fatigue in active young men. A systematic review distinguishes biochemical signals from inconsistent clinical performance evidence.
- Branched-chain amino acid supplementation and endurance performance: reporting guidelines and systematic review of biochemical vs clinical evidence.
PMID 41655197 · 2026 · systematic review / meta-analysisShort trials report better cycling in untrained participants and altered substrate use/less fatigue in active young men. A systematic review distinguishes biochemical signals from inconsistent clinical performance evidence.
- The Association between Circulating Branched Chain Amino Acids and the Temporal Risk of Developing Type 2 Diabetes Mellitus: A Systematic Review & Meta-Analysis.
PMID 36297095 · 2022 · systematic review / meta-analysis of observational studiesHigher circulating BCAA predict type 2 diabetes observationally; this may mark impaired metabolism and does not prove supplements cause diabetes. The overweight/obesity supplementation RCT found no metabolic benefit.
- Branched-Chain Amino Acid Supplementation Does Not Preserve Lean Mass or Affect Metabolic Profile in Adults with Overweight or Obesity in a Randomized Controlled Weight Loss Intervention.
PMID 33537760 · 2021 · randomized controlled trialHigher circulating BCAA predict type 2 diabetes observationally; this may mark impaired metabolism and does not prove supplements cause diabetes. The overweight/obesity supplementation RCT found no metabolic benefit.
- Optimizing Body Composition During Weight Loss: The Role of Amino Acid Supplementation.
PMID 40573110 · 2025 · narrative reviewThe weight-loss RCT did not preserve lean mass or improve metabolic profile. Amino-acid marketing does not establish fat loss or anticatabolic protection.
- Nutritional Interventions to Improve Cachexia Outcomes in Cancer-A Systematic Review.
PMID 35888685 · 2022 · systematic review / meta-analysisA systematic review found limited, mixed evidence for nutritional interventions including BCAA in cancer cachexia; clinical supervision is essential.
- Branched-chain amino acid supplementation as a potential trigger for migraine without aura: a case report.
PMID 42316353 · 2026 · case reportA single case report describes migraine without aura after BCAA supplementation. This is a possible adverse signal, not established causation or treatment evidence.
- The molecular mechanism of intestinal levodopa absorption and its possible implications for the treatment of Parkinson's disease.
PMID 25073474 · 2014 · animal studyBCAA and other large neutral amino acids compete with levodopa transport. Review high-dose supplements with the treating Parkinson disease team; the cataloged molecular study is mechanistic/preclinical.
- Beneficial effect of branched-chain amino acid supplementation on glycemic control in chronic hepatitis C patients with insulin resistance: implications for type 2 diabetes.
PMID 22520843 · 2012 · randomized controlled trialA chronic-hepatitis-C insulin-resistance trial reported glycemic changes, while an obesity weight-loss trial found no metabolic benefit. Do not generalize either to a reliable diabetes treatment or quantified drug interaction.
Community comments
No approved comments yet. Comments are held for moderation.